NanoViricides, Inc. (NNVC.OTCBB) is working in the general field of Nanomedicine. This is a very diverse field and encompasses a wide range of materials and applications. Specifically, we are working in the area of targeted anti-viral therapeutics. Utilizing nanoscale materials and processes licensed from TheraCour Pharma, Inc., we are developing anti-viral drugs against a wide range range of human and animal viruses.
NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.
NanoViricides, Inc. is a development stage company. The Company’s novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, Epidemic Kerato-Conjunctivitis (EKC), hepatitis C, rabies, dengue fever, and Ebola virus, among others.
A “nanoviricide™” is a flexible nano-scale material approximately a few billionths of a meter in size, which is chemically programmed to specifically target and attack a particular type of virus like a guided missile. A lot of development work is required for each drug candidate from the stage of designing it to obtaining regulatory approvals (e.g. US FDA) for use as a drug in humans.
Targeted nanoviricide against human influenza. The company’s development goals include the development of a drug that will have the ability to completely neutralize and disable the viral particles in the bloodstream and lungs.
The company’s development goals are to produce a targeted nanoviricide that attacks, neutralizes and disables the Hepatitis C virus. Hepatitis C virus is known to attack liver cells and is linked to liver cancer.
The company’s development goals are to develop a drug against bird (avian) influenza.
Targeted nanoviricide directed against the Highly Pathogenic (most dangerous) form of various influenzas. The company’s development goals are to neutralize and disable the viral particles in the bloodstream and the lungs.
The company’s development goals are to produce a targeted nanoviricide directed against the HIV viruses.
Targeted nanoviricide directed against the rabies virus.
For more information, visit: http://www.nanoviricides.com/